- |||||||||| AN4005 / Adlai Nortye
Trial completion date, Trial primary completion date, Metastases: AN4005X0101: First in Human, Dose Escalation Study of AN4005 (clinicaltrials.gov) - Oct 23, 2024
P1, N=31, Recruiting,
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
- |||||||||| AN4005 / Adlai Nortye
A phase I study of AN4005, an orally available PD-L1 inhibitor, in patients with advanced tumors: safety and preliminary efficacy (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_1014;
P1
All patients enrolled gave informed consent before participating. The IRB/IEC approval numbers were: IRB Tracking Number 20213975 (WCG IRB); Event ID # 189834 (BRANY IRB); NXVCS21.53 (Salus IRB); IEC Number 2022-78 (Harbin Medical University Cancer Hospital); IEC Number 2022-0251 (Union Hospital, Tongji Medical College, Huazhong University of Science and Technology).View this table:View inline View popup Download powerpoint Abstract 691 Table 1 Number of patients per tested dose levelView this table:View inline View popup Download powerpoint Abstract 691 Table 2 Treatment-related adverse events (TRAEs) reported in ?2 patients across all dose levels (N=24)View this table:View inline View popup Download powerpoint Abstract 691 Table 3 Summary of best overall response (BOR) per RECIST 1.1 by dose level
- |||||||||| AN4005 / Adlai Nortye
Trial completion date, Trial primary completion date, Metastases: AN4005X0101: First in Human, Dose Escalation Study of AN4005 (clinicaltrials.gov) - Jun 27, 2024
P1, N=31, Recruiting,
The IRB/IEC approval numbers were: IRB Tracking Number 20213975 (WCG IRB); Event ID # 189834 (BRANY IRB); NXVCS21.53 (Salus IRB); IEC Number 2022-78 (Harbin Medical University Cancer Hospital); IEC Number 2022-0251 (Union Hospital, Tongji Medical College, Huazhong University of Science and Technology).View this table:View inline View popup Download powerpoint Abstract 691 Table 1 Number of patients per tested dose levelView this table:View inline View popup Download powerpoint Abstract 691 Table 2 Treatment-related adverse events (TRAEs) reported in ?2 patients across all dose levels (N=24)View this table:View inline View popup Download powerpoint Abstract 691 Table 3 Summary of best overall response (BOR) per RECIST 1.1 by dose level Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: May 2024 --> Aug 2024
- |||||||||| AN4005 / Adlai Nortye
Trial primary completion date, Metastases: AN4005X0101: First in Human, Dose Escalation Study of AN4005 (clinicaltrials.gov) - Mar 12, 2024
P1, N=31, Recruiting,
Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: May 2024 --> Aug 2024 Trial primary completion date: Feb 2024 --> May 2024
- |||||||||| AN4005 / Adlai Nortye
Trial completion date, Trial primary completion date, Metastases: AN4005X0101: First in Human, Dose Escalation Study of AN4005 (clinicaltrials.gov) - Jul 28, 2023
P1, N=31, Recruiting,
Trial primary completion date: Feb 2024 --> May 2024 Trial completion date: Aug 2023 --> Jun 2024 | Trial primary completion date: May 2023 --> Dec 2023
- |||||||||| AN4005 / Adlai Nortye
Trial primary completion date, Metastases: AN4005X0101: First in Human, Dose Escalation Study of AN4005 (clinicaltrials.gov) - Oct 24, 2022
P1, N=31, Recruiting,
Trial completion date: Aug 2023 --> Jun 2024 | Trial primary completion date: May 2023 --> Dec 2023 Trial primary completion date: Aug 2022 --> May 2023
|
